These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15179453)

  • 1. The potential of bacterial fatty acid biosynthetic enzymes as a source of novel antibacterial agents.
    Payne DJ
    Drug News Perspect; 2004 Apr; 17(3):187-94. PubMed ID: 15179453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A view of development of new antibacterial agents with novel targets].
    Watanabe Y; Minami S
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():248-53. PubMed ID: 12717979
    [No Abstract]   [Full Text] [Related]  

  • 4. Triclosan: a widely used biocide and its link to antibiotics.
    Schweizer HP
    FEMS Microbiol Lett; 2001 Aug; 202(1):1-7. PubMed ID: 11506900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
    Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
    Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
    Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
    Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors.
    Kapoor M; Dar MJ; Surolia A; Surolia N
    Biochem Biophys Res Commun; 2001 Dec; 289(4):832-7. PubMed ID: 11735121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradigm shifts in malaria parasite biochemistry and anti-malarial chemotherapy.
    Surolia N; RamachandraRao SP; Surolia A
    Bioessays; 2002 Feb; 24(2):192-6. PubMed ID: 11835284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reductase steps of the type II fatty acid synthase as antimicrobial targets.
    Zhang YM; Lu YJ; Rock CO
    Lipids; 2004 Nov; 39(11):1055-60. PubMed ID: 15726819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum.
    Surolia N; Surolia A
    Nat Med; 2001 Feb; 7(2):167-73. PubMed ID: 11175846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial targets in fatty acid biosynthesis.
    Wright HT; Reynolds KA
    Curr Opin Microbiol; 2007 Oct; 10(5):447-53. PubMed ID: 17707686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli.
    Tasdemir D; Topaloglu B; Perozzo R; Brun R; O'Neill R; Carballeira NM; Zhang X; Tonge PJ; Linden A; Rüedi P
    Bioorg Med Chem; 2007 Nov; 15(21):6834-45. PubMed ID: 17765547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids.
    Zheng CJ; Yoo JS; Lee TG; Cho HY; Kim YH; Kim WG
    FEBS Lett; 2005 Sep; 579(23):5157-62. PubMed ID: 16146629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mechanism of drug action revealed by structural studies of enoyl reductase.
    Baldock C; Rafferty JB; Sedelnikova SE; Baker PJ; Stuitje AR; Slabas AR; Hawkes TR; Rice DW
    Science; 1996 Dec; 274(5295):2107-10. PubMed ID: 8953047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtually Designed Triclosan-Based Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis and of Plasmodium falciparum.
    Owono Owono LC; Ntie-Kang F; Keita M; Megnassan E; Frecer V; Miertus S
    Mol Inform; 2015 May; 34(5):292-307. PubMed ID: 27490275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Old and new anti-mycobacterial drugs. Fatty acid synthesis as a target].
    Topf CM; Schiebel J; Kisker C; Holzgrabe U
    Pharm Unserer Zeit; 2012 Jan; 41(1):64-70. PubMed ID: 22470920
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New agents to combat malaria.
    Beeson JG; Winstanley PA; McFadden GI; Brown GV
    Nat Med; 2001 Feb; 7(2):149-50. PubMed ID: 11175835
    [No Abstract]   [Full Text] [Related]  

  • 19. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.
    Argyrou A; Vetting MW; Blanchard JS
    J Am Chem Soc; 2007 Aug; 129(31):9582-3. PubMed ID: 17636923
    [No Abstract]   [Full Text] [Related]  

  • 20. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery.
    Campbell JW; Cronan JE
    Annu Rev Microbiol; 2001; 55():305-32. PubMed ID: 11544358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.